These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16920253)

  • 1. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.
    Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; Malmström PU; de Kok JB
    Eur Urol; 2007 Feb; 51(2):416-22; discussion 422-3. PubMed ID: 16920253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence.
    Schultz IJ; De Kok JB; Witjes JA; Babjuk M; Willems JL; Wester K; Swinkels DW; Tjalsma H
    Anticancer Res; 2007; 27(2):1051-8. PubMed ID: 17465243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
    Schultz IJ; Kiemeney LA; Witjes JA; Schalken JA; Willems JL; Swinkels DW; de Kok JB
    Anticancer Res; 2003; 23(4):3327-31. PubMed ID: 12926071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study.
    Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; de Kok JB; Malmström PU
    Int J Cancer; 2006 Oct; 119(8):1915-9. PubMed ID: 16721812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.
    Rouprêt M; Hupertan V; Yates DR; Comperat E; Catto JW; Meuth M; Lackmichi A; Ricci S; Lacave R; Gattegno B; Richard F; Hamdy FC; Cussenot O
    BJU Int; 2008 Jun; 101(11):1448-53. PubMed ID: 18325051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas.
    Kitsukawa S; Aoyagi T; Noda K; Ito T; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T
    Hinyokika Kiyo; 2008 Feb; 54(2):101-6. PubMed ID: 18323166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients.
    Li CC; Chang TH; Wu WJ; Ke HL; Huang SP; Tsai PC; Chang SJ; Shen JT; Chou YH; Huang CH
    Eur Urol; 2008 Nov; 54(5):1127-34. PubMed ID: 18243511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.
    Marín-Aguilera M; Mengual L; Ribal MJ; Ars E; Ríos J; Gázquez C; Villavicencio H; Alcaraz A
    Urology; 2012 Jan; 79(1):240.e9-15. PubMed ID: 22055693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
    Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
    Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
    Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
    Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 predictive value for pT1-2 N0 disease at radical cystectomy.
    Shariat SF; Lotan Y; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Müller SC; Karam JA; Heukamp LC; Netto G; Lerner SP; Sagalowsky AI; Cote RJ
    J Urol; 2009 Sep; 182(3):907-13. PubMed ID: 19616250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.
    Skagias L; Politi E; Karameris A; Sambaziotis D; Archondakis A; Ntinis A; Moreas I; Vasou O; Koutselini H; Patsouris E
    Anticancer Res; 2009 Oct; 29(10):4163-7. PubMed ID: 19846967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
    Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
    J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
    Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
    J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
    Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
    J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
    Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
    J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.